FORWARD-LOOKING STATEMENTS
|
|
- Oscar Greer
- 5 years ago
- Views:
Transcription
1 NOVEMBER
2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. 2
3 BAVARIAN NORDIC S GOAL To develop innovative and safe therapies against cancer and infectious diseases; to improve the health and quality of life for children and adults. CANCER INFECTIOUS DISEASES PROSTVAC improving survival HPV preventing cancer before it starts RSV protecting the broader population against diseases with no approved therapies CV301 & Brachyury in combination therapies potentially curing cancer Smallpox / Ebola preparation and protection against global pandemic threats HIV / HBV seeking a functional cure 3
4 THE STRATEGY 1 Maintain the global leadership of our smallpox vaccine franchise Awarded freeze-dried contract from BARDA Investing in fill/finish line securing future manufacturing requirements 2 Rapidly advance our pipeline of infectious disease programs Completed Phase 2 and outlined development strategy for RSV Expanded collaboration with Janssen on HIV & HBV 3 Establishing a broad and deep cancer immunotherapy franchise Industry and sponsor collaborations for combination studies of CV301 in multiple indications Advancing BN-Brachyury into Phase 2 PROSTVAC Phase 3 monotherapy discontinued Initiated two combination studies of PROSTVAC with checkpoint inhibitors from Bristol-Myers Squibb Strong financial position enables executing on strategy going forward 4
5 CLINICAL PIPELINE PRODUCT INFECTIOUS DISEASES INDICATION ONGOING STUDIES PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET COMMERCIAL RIGHTS IMVAMUNE liquid-frozen 1) Smallpox 2 IMVAMUNE freeze-dried Smallpox - MVA-BN Filo Ebola/Marburg 13 MVA-BN RSV RSV 1 CANCER IMMUNOTHERAPY PROSTVAC mono/combo Prostate Cancer 10 CV301 + anti-pd-1 Lung Cancer (NSCLC) 1 CV301 + anti-pd-l1 Bladder Cancer - Planned 2018 BN-Brachyury Metastatic Tumors 1 BN-Brachyury Chordoma - Planned ) Approved in the European Union under the trade name IMVANEX and in Canada under the trade name IMVAMUNE. Phase 3 registration studies are ongoing in the United States. 5
6 PRECLINICAL COLLABORATIONS PRODUCT INDICATION PRECLINICAL COLLABORATION COMMERCIAL RIGHTS INFECTIOUS DISEASES MVA-BN HPV + AdVac Chronic HPV infection MVA-BN HBV + AdVac Hepatitis B MVA-BN HIV + AdVac HIV-1 6
7 OUR VACCINE PLATFORM Unprepared, weakened, or failing immunity Upgraded Immunity allows body to identify and attack specific diseases 7
8 OUR VACCINE PLATFORM Approved platform Applicable to cancer or infectious diseases Can stimulate broad and sustained immune responses Well tolerated Based on large viruses which allows for larger payloads Ability to encode multiple targets for specific diseases Other platforms are much more limited Validated and approved manufacturing facility Multi-purpose facility capable of producing all clinical materials Over 28m doses of IMVAMUNE and 2m doses of MVA-Ebola, to date. Highly customizable approach to curing diseases 8
9 BROAD PARTNERSHIPS IN THERAPEUTIC VACCINES Development of IMVAMUNE and procurement for national stockpile Research and development agreement on PROSTVAC, CV301 and Brachyury Ebola license and production agreement HPV, HIV & HBV license agreements Option license agreement on PROSTVAC, including clinical collaboration - still to be decided by partner 9
10 OUR COLLABORATION WITH JANSSEN A LONG-TERM VALUE DRIVER MVA-BN Filo (Ebola) License & Supply Agreement US$ 119m + Upfront US$ 25m Equity investment US$ 43m 2014 MVA-BN HPV License Agreement US$ 162m MVA-BN HIV Upfront US$ 9m Potential milestone payments of more than US $1BN + royalties License Agreement US$ 606m MVA-BN HBV 2017 License Agreement US$ 230m + Upfront US$10m Equity investment US$ 33m
11 Non-replicating smallpox vaccine for national stockpiles Indicated for persons with compromised immune systems (but also healthy individuals) 28 million doses produced and delivered to the U.S. Approved in EU and Canada Phase 3 ongoing in the U.S. 11
12 IMVAMUNE PARTNERSHIP WITH THE U.S. GOVERNMENT Freeze-dried Bulk supply $333m Fill-finish Clinical/Reg & Prod support $439m Additional bulk &/or IMVAMUNE doses Approval CDC procurement 132 million doses Representing ~ 13 million doses of FD IMVAMUNE 2018 and beyond US strategic long-term stockpiling goal, as outlined by BARDA. Liquid-frozen Delivered 28M IMVAMUNE doses Positive Phase 3 (POX-MVA-006) FDA approval and award of a PRV
13 ESTABLISHMENT OF FILL-FINISH CAPACITY Taking full control of value chain in manufacturing BN will invest approx. USD 75 million in a fill-finish line at its existing facility in Denmark Contract options of USD 33 million for process transfer and validation of the new manufacturing line Secures deliverables for future supply orders and pipeline assets Capacity for handling both liquidfrozen and freeze-dried products 13
14 RSV represents a high unmet medical need; similar disease burden and death rate in the elderly population as influenza 14 Phase 1 data demonstrated safety and tolerability Positive data from 421 subject Phase 2 trial show durable response
15 RSV A LARGE UNMET MEDICAL NEED DEATH RATE OF RSV SIMILAR TO THAT OF INFLUENZA RSV Influenza Pneumonia Deaths # of infections Hospitalizations No approved prophylactic vaccine $5.4B USD global market ~$6B USD global annual sales (Prevnar) 15
16 Geometric Mean Fold Increase (GMFI) RSV IgG ELISA [GMT] AT THE FOREFRONT OF RSV VACCINE DEVELOPMENT Competitive advantages Designed to mimic natural RSV infection: Induction of T-cells and antibodies against RSV Induction of mucosal immunity Balanced vaccine construct Encodes 5 distinct targets of RSV to provide protection against multiple antigens providing a balanced T-cell and antibody response Durable immune response lasting an RSV season F (A) G (A) G (B) N M2 Robust T-cell and antibody responses demonstrated in Phase 1 and 2 studies 17,0 15,0 13,0 11,0 9,0 7,0 5,0 3,0 1,0 RSV-specific T cell response RSV RSV F RSV N RSV G(A) RSV G(B) RSV M2 Antibody responses demonstrated over a full RSV season (Phase 2) RSV-specific total IgG Antibody Titers High / Placebo (N=80) Placebo (N=83) Week 16
17 PHASE 2 BOOSTER STUDY Key objectives of booster study Get clarity on long-term durability of immune response (12 months following primary vaccination) Evaluate effect of a single booster dose after primary vaccination with a single shot using same dose as in the main study (N=86) 1 x 10 8 Day 0 Placebo Day 28 Adult population 55 years of age; N=80 per group IM administration of vaccine or placebo on Day 0 and Day 28 1 x 10 8 Day 0 1 x 10 8 Day 28 Randomization 5 x 10 8 Day 0 Placebo Day 28 5 x 10 8 Day 0 5 x 10 8 Day 28 Placebo Day 0 Placebo Day 28 Main Study Primary vaccination Booster 1 x 10 8 Booster 5 x 10 8 N=43 N=43 Booster study 1-year durability and booster 17
18 DEVELOPING A HUMAN CHALLENGE TRIAL FOR RSV PREPARATION FOR PHASE 3 Strategy Collaboration to develop a human challenge model Prior success in the development of a flu challenge model Healthy volunteers will be intranasally infected with a strain of RSV Monitored for viral load, immune markers and clinical symptoms Key advantages compared to field trials Well-defined viral infectivity, independent of RSV season Close monitoring of onset, severity and duration of disease symptoms Intensive sampling of immune responses Rapid, small sample size, cost-effective Benefits Provides important learnings for Phase 3 design Mitigates the risk in progressing to large, costly field efficacy trials Potential for accelerated approval 18
19 MVA-BN RSV DEVELOPMENT STRATEGY FOR ELDERLY INDICATION Generate 12 months FU and booster data in ongoing Ph2 Conduct a human challenge trial (HCT) Agree on Ph3 field efficacy design during EoP2 with FDA Evaluate HCT topline data in 2018 Initiate Ph3 field efficacy Enroll number of subjects needed for futility testing Follow-up for symptomatic RSV cases through the 2019/2020 RSV season Continue Ph3 field efficacy into 2 nd season Follow-up for symptomatic RSV cases through the 2020/2021 RSV season 19
20 Studies from two decades of research have demonstrated our cancer vaccines to be well tolerated and have shown promise in extending overall survival Our vaccine platform has been found to be a potent stimulator of T-cells directed at particular tumor targets, breaking tolerance and inflaming tumors 20
21 PROSPECT - BLINDED OVERALL SURVIVAL (ALL GROUPS) Reference OS in mcrpc (pre-chemo) Abiraterone NR (>27.2 months) Placebo 27.2 months COU-AA-302 Ryan et al. NEJM 2013 Median Survival = 33.9 months Enzalutamide 32.4 months Placebo 30.2 months PREVAIL Beer et al., NEJM 2014 Ipilimumab 28.7 months Placebo 29.8 months CA Beer et al., JCO 2016 Sipuleucel-T 25.8 months Placebo 21.7 months IMPACT Kantoff et al., NEJM 2010 Why didn t we see improved OS? --vaccine doesn t work --subsequent therapies diluted signal 21
22 PROSTVAC INDUCES AN ANTIGEN CASCADE AGAINST PROSTATE CANCER CELLS Summary of T-cell responses from six PROSTVAC clinical trials Test Result Comment PSA-Specific Immune response 56.7% (59/104) 28 days after last vaccine Median fold increase in PSAspecific immune response 5X PSA response 30 / 10 6 cells flu response 33 / 10 6 cells Antigen Cascade 67.9% (19/28) New T cells generated against new tumor antigens (non-psa) Anti-PSA Ab 0.57% (2/349) Gulley et al., Immune impact by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2:
23 Survival (% of patients) DEMONSTRATED POTENTIAL AS A COMBINATION THERAPY WITH CHECKPOINT INHIBITORS PROSTVAC + ipilimumab Phase 1 Trial PSA Waterfall Plot: ipi/prostvac PROSTVAC + Ipi (all Ipi dose cohorts) 31.6 months Madan Schlom, Gulley, Lancet Oncology, Months Ongoing Phase 2 (n=29) 30 mcrpc Patients: Predicted survival average: 18.5 months 2 Phase 3 studies of Ipilimumab in prostate cancer did not show significant OS benefit Gulley J, NCI. Madan RA, et al. Lancet Oncol. 2012;3: Lead-in mcrpc Cohort Neoadjuvant Cohort Sponsor: NCI NCT PROSTVAC + nivo PROSTVAC + nivo
24 PROSTVAC STUDIES PHASE 3 ANALYSIS CURRENTLY ONGOING Phase 3 study Monotherapy Combination study Completed study Non-metastatic Metastatic 8 completed 10 ongoing DOCETAXEL JEVTANA XTANDI XOFIGO Surgery LUPRON DOCETAXEL PROVENGE ZYTIGA XGEVA 24
25 Vaccines targeting multiple solid tumour indications Aligning combination treatments to reflect the commercial landscape 25
26 CV301 PRIME/BOOST CEA & MUC-1 TARGETED OFF THE SHELF CANCER VACCINE TRICOM CEA MUC-1 LFA-3 ICAM-1 B7.1 M F Heterologous prime/boost regimen MVA-BN (M) + Fowlpox (F) Subcutaneous administration CEA & MUC-1 Tumor antigens overexpressed in the majority of solid tumors Lung, bladder, colorectal, breast, ovarian, pancreatic, renal and head & neck indications TRICOM (TRIad of COstimulatory Molecules) Enhance T-Cell activation in synergistic manner Strengthen the anticancer immune response Safe and well tolerated (9 completed & ongoing clinical trials) Injection site reactions and flulike symptoms 26
27 CV301 IMMUNOTHERAPY PLATFORM WITH POTENTIAL IN MULTIPLE SOLID TUMORS Our goal is to become preferred treatment in combination with multiple checkpoint inhibitors (CPI) Strong preclinical evidence of combination synergies Opportunity to convert the CPI non-responders Exploring combinations in company collaborations or with NCI Multiple near and long-term data points (ORR, DoR, PFS, OS) Non-small cell lung cancer (NSCLC) Proof-of-concept study of CV301 plus KEYTRUDA (pembrolizumab) as firstline maintenance therapy (n=176) Bladder cancer Phase 2 single-arm study of CV301 plus TECENTRIQ (atezolizumab) (n=60) Other potential indications In addition to NSCLC and bladder, Bavarian Nordic retains all commercial rights in colorectal, pancreatic, breast, ovarian, gastric, liver and renal cancer 27
28 REVISED PROOF-OF-CONCEPT STUDY OF CV301 & KEYTRUDA IN FIRST LINE MAINTENANCE NSCLC Phase 1 - Completed Safety CV301 single agent (n=12) Phase 1b - Ongoing Single dose combinations of both CV301 with OPDIVO and CV301 with KEYTRUDA (n=6 pt each arm) Phase 2 Multi-center trial. Up to 20 sites in USA (n=176) Cohort 1 (n=53): High PD-L1 expression Randomize 1:2 Cohort 2 (n=123) Randomize 1:2 KEYTRUDA n=18 KEYTRUDA + CV301 n=35 KEYTRUDA ± Pemetrexed n=41 KEYTRUDA + CV301 ± Pemetrexed n=82 Endpoints remain the same: Safety, tolerability Primary endpoint: OS Secondary endpoints: ORR, DOR, PFS, Immune effects 28
29 COMPLETE TUMOR REGRESSION FROM POXVIRUS-BASED IMMUNOTHERAPY COMBINED WITH PD-1 & LAG-3 BLOCKADE MVA-BN-HER2 20/20 + anti-pd1 + anti-lag3 anti-pd1 + 14/20 anti-lag3 CT26-HER2 solid tumor model: MVA-BN-HER2 immunotherapy (s.c.) and/or anti-pd1 + anti- LAG3 antibody (i.p.) Q2wks x2 (d1 and 15) Control MVA-BN-HER2 2/20 Durable response after mice were rechallenged 29
30 BRACHYURY PRIME/BOOST BRACHYURY TARGETED OFF THE SHELF CANCER VACCINE TRICOM Brachyury LFA-3 ICAM-1 B7.1 M F Heterologous prime/boost regimen MVA-BN (M) + Fowlpox (F) Subcutaneous administration Brachyury Tumor antigens overexpressed in the majority of solid tumors Lung, bladder, colorectal, breast, ovarian, pancreatic, renal and head & neck indications TRICOM (TRIad of COstimulatory Molecules) Enhance T-Cell activation in synergistic manner Strengthen the anticancer immune response Safe and well tolerated (Phase I completed) Injection site reactions and flulike symptoms 30
31 BN-BRACHYURY NOVEL IMMUNOTHERAPY TARGETING THE METASTATIC PROCESS Brachyury expression is highly correlated with metastatic disease, and multi-drug resistance Brachyury is not expressed in most normal tissue Brachyury is responsible for epithelial to mesenchymal transition (EMT), which is a major driver of metastasis A Phase 1 study of 38 patients receiving MVA-BN Brachyury showed presence of brachyury specific T-cells in vast majority of patients, post-treatment. Potential indications: Triple negative breast cancer Other breast cancer Small cell lung cancer Neuroendocrine tumors Merkel Cell Carcinoma Non-small cell lung cancer Hepatocellular carcinoma Colorectal cancer Head and neck/oral 31
32 BN-BRACHYURY CLINICAL TRIAL PLANS Transitioning to prime-boost regimen Phase 1 planned to initiate by end 2017 Adding fowlpox (FPV) booster to construct Safety evaluation expected Q Immune response data Q Goal demonstrate persistent brachyury-specific T-cell activation with boost Phase 2 with prime-boost vaccine planned to initiate Q Combination with radiation in advanced chordoma Primary endpoint: Objective response rate (radiation alone <5% ORR at 6 months) Potential for Breakthrough Designation Expect to initiate enrollment Q Combination with PD-1/L1 in various indications planned 32
33 FINANCIAL PERFORMANCE AND GUIDANCE Consistent with previous years we have generated revenues above DKK 1 billion and recorded a break-even result Cash preparedness has more than tripled over the last three years 2017 guidance Revenues: DKK 1,300 million EBIT: DKK 350 million Cash preparedness, year-end: DKK 2,600 million mdkk mdkk E E Revenue EBIT Cash preparedness 33
34 ANTICIPATED SELECTED MILESTONES H H H RSV Data: booster study Initiate challenge study EOP2 FDA to determine registration pathway for elderly Top-line efficacy data from challenge study Ongoing preparations to initiate phase 3 IMVAMUNE Top-line data for Phase 3 non-inferiority study Approval and Priority Review Voucher CV301 Phase 2 initiation of CV301 and KEYTRUDA in first-line NSCLC Phase 1 data of CV301 and OPDIVO Phase 2 initiation of CV301 and TECENTRIQ Phase 2 data (ORR) for CV301 and KEYTRUDA Phase 2 data (PFS) for CV301 and KEYTRUDA Phase 2 data (ORR) for CV301 and TECENTRIQ Brachyury Initiate fowlpox booster study Data from fowlpox booster study Initiate study in Chordoma Initiate study in 2 nd indication PROSTVAC Emerging data from NCIsponsored Phase 2 34
35 YTD PERFORMANCE 30% 25% 20% 15% 10% 5% 0% -5% -10% -15% -20% NOVO LUN GEN ALK BAVA ZEAL 35
36 5 YR PERFORMANCE 1600% 1400% 1200% 1000% 800% 600% 400% 200% 0% NOVO LUN GEN ALK BAVA ZEAL 36
37 VALUE DISTRIBUTION Pipeline and assets for free DKK billion ,2 J&J contracts DKK 4.7 bn ~ DKK 146 per share 6 4 7,5 3,4 IMVAMUNE contracts Current market cap 2,6 Cash + contracts Cash position
38 38
FORWARD-LOOKING STATEMENTS
DECEMBER 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could
More informationFORWARD-LOOKING STATEMENTS
NOVEMBER 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationCITI EUROPEAN HEALTHCARE CONFERENCE JUNE 2017
CITI EUROPEAN HEALTHCARE CONFERENCE 2017 20 JUNE 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which
More informationINTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationTHE FUTURE OF VACCINES DECEMBER 2016
THE FUTURE OF VACCINES DECEMBER 2016 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationINTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF MARCH 31, 2014 Q1 MAY 14, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 1.7 million doses delivered to the SNS during Q1 Full year financial expectations maintained DKK million
More informationTHE FUTURE OF VACCINES JANUARY 2016
THE FUTURE OF VACCINES JANUARY 2016 1 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation constitute forward-looking
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationCONTROLLING THE IMMUNE RESPONSE IN GI CANCERS
CONTROLLING THE IMMUNE RESPONSE IN GI CANCERS Christopher Heery, MD Head, Clinical Trials Group Laboratory of Tumor Immunology and Biology National Cancer Institute Bethesda, MD Tumor Immunology Overview
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationMagazine CELEBRATIONS CEO and President Anders Hedegaard looks back on a year with several landmark events for the company.
A YEAR OF CELEBRATIONS CEO and President Anders Hedegaard looks back on a year with several landmark events for the company. PAGE04 Magazine 2013 Bavarian Nordic IMVAMUNE FIRST 20 MILLION DOSES NOW DELIVERED
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 1 Forward-Looking Statement Disclosure Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends,
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationTargeting the Tumor Locally
ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationDevelopment of MVA-VLP Vectors for Cancer Immunotherapy
Farshad Guirakhoo, PhD fguirakhoo@geovax.com 678-384-7229 Development of MVA-VLP Vectors for Cancer Immunotherapy Executive Summary Cancer is the second most common cause of death in the US, exceeded only
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationPROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer
PROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer James L. Gulley M.D., Ph.D., F.A.C.P. Director, Clinical Trials
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationOPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES
OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES Dr. Robert P. Kadlec Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services 2017 Chemical and
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationRoche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCowen Health Care Conference
Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationHALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More information